Macquarie Group Ltd. lowered its holdings in Flexion Therapeutics Inc (NASDAQ:FLXN) by 16.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,976 shares of the specialty pharmaceutical company’s stock after selling 8,941 shares during the period. Macquarie Group Ltd. owned approximately 0.13% of Flexion Therapeutics worth $1,136,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Fiduciary Trust Co. bought a new stake in shares of Flexion Therapeutics in the second quarter valued at approximately $101,000. IFP Advisors Inc raised its position in shares of Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,000 shares during the period. Advisor Group Inc. raised its position in shares of Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares during the period. SG Americas Securities LLC bought a new stake in shares of Flexion Therapeutics in the third quarter valued at approximately $135,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Flexion Therapeutics in the third quarter valued at approximately $235,000. 72.82% of the stock is currently owned by institutional investors.
Flexion Therapeutics Inc (FLXN) opened at $25.47 on Friday. Flexion Therapeutics Inc has a 12 month low of $16.51 and a 12 month high of $32.25. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87.
In related news, insider Neil Bodick purchased 2,700 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was acquired at an average price of $24.49 per share, with a total value of $66,123.00. Following the purchase, the insider now directly owns 64,605 shares in the company, valued at $1,582,176.45. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael D. Clayman purchased 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the purchase, the insider now owns 35,395 shares in the company, valued at $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is currently owned by insiders.
Several analysts have recently issued reports on the stock. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Needham & Company LLC boosted their price target on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 9th. Finally, Northland Securities reissued a “buy” rating and issued a $40.00 price target on shares of Flexion Therapeutics in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Flexion Therapeutics presently has an average rating of “Buy” and an average price target of $98.33.
TRADEMARK VIOLATION WARNING: “Macquarie Group Ltd. Lowers Stake in Flexion Therapeutics Inc (FLXN)” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2017/12/09/macquarie-group-ltd-lowers-stake-in-flexion-therapeutics-inc-flxn.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.